Compare Stocks

→ The only accurate crypto trading system I know … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADRO Aduro Biotech		$10.93	$4.51 ▼ $20.20	$236.61M	0.4	162,237 shs	171,500 shs
EVFM Evofem Biosciences	$0.02	$0.02	$0.01 ▼ $4.05	$831K	-1.12	766,391 shs	369,086 shs
LXRX Lexicon Pharmaceuticals	$1.65 +1.2%	$2.36	$0.92 ▼ $3.79	$406.30M	1.27	3.13 million shs	2.99 million shs
OSMT Osmotica Pharmaceuticals		$1.16	$0.98 ▼ $4.95	$69.47M	2.34	396,682 shs	296,500 shs
SNDX Syndax Pharmaceuticals	$20.80 +1.5%	$22.80	$11.22 ▼ $25.34	$1.77B	1.03	945,146 shs	942,562 shs

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADRO Aduro Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
EVFM Evofem Biosciences	+9.22%	+2.67%	-2.53%	-60.76%	-99.61%
LXRX Lexicon Pharmaceuticals	+1.23%	-16.24%	-33.73%	+26.92%	-35.80%
OSMT Osmotica Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
SNDX Syndax Pharmaceuticals	+1.51%	-4.24%	-9.68%	+0.58%	0.00%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADRO Aduro Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	0.9408 of 5 stars	3.0	1.0	0.0	0.0	1.8	1.7	0.6
OSMT Osmotica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	2.9069 of 5 stars	3.5	1.0	0.0	4.4	0.8	0.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADRO Aduro Biotech	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	2.00	Hold	N/A	N/A
LXRX Lexicon Pharmaceuticals	2.00	Hold	$5.00	203.03% Upside
OSMT Osmotica Pharmaceuticals	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$34.42	65.46% Upside

Current Analyst Ratings

Latest LXRX, SNDX, EVFM, ADRO, and OSMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
3/27/2024	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00
3/20/2024	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$31.00 ➝ $34.00
2/28/2024	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00
1/31/2024	SNDX Syndax Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$36.00 ➝ $23.00

(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADRO Aduro Biotech	$17.26M	0.00	N/A	N/A	$4.07 per share	0.00
EVFM Evofem Biosciences	$18.22M	0.05	$1.54 per share	0.01	($2.64) per share	-0.01
LXRX Lexicon Pharmaceuticals	$1.20M	338.58	N/A	N/A	$0.38 per share	4.34
OSMT Osmotica Pharmaceuticals	$177.88M	0.00	N/A	1.00	$1.50 per share	0.00
SNDX Syndax Pharmaceuticals	$139.71M	12.65	N/A	N/A	$6.53 per share	3.19

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADRO Aduro Biotech	-$82.37M	-$5.15	N/A	N/A	N/A	-230.92%	-101.73%	-22.35%	N/A
EVFM Evofem Biosciences	$52.98M	-$7.62	N/A	∞	N/A	290.81%	-90.20%	331.20%	4/26/2024 (Estimated)
LXRX Lexicon Pharmaceuticals	-$177.12M	-$0.80	N/A	N/A	N/A	-14,573.20%	-138.54%	-71.29%	5/7/2024 (Estimated)
OSMT Osmotica Pharmaceuticals	-$79.59M	-$1.59	N/A	N/A	N/A	-138.76%	-81.23%	-20.97%	N/A
SNDX Syndax Pharmaceuticals	-$209.36M	-$2.96	N/A	N/A	N/A	N/A	-47.88%	-44.00%	5/13/2024 (Estimated)

Latest LXRX, SNDX, EVFM, ADRO, and OSMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/27/2024	Q4 2023	EVFM Evofem Biosciences	N/A	-$0.44	-$0.44	-$0.44	N/A	$4.84 million
3/11/2024	Q4 2023	LXRX Lexicon Pharmaceuticals	-$0.23	-$0.20	+$0.03	-$0.20	$0.68 million	$0.70 million
2/27/2024	Q4 2023	SNDX Syndax Pharmaceuticals	-$0.99	-$1.00	-$0.01	-$1.00	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADRO Aduro Biotech	N/A	N/A	N/A	N/A	N/A
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OSMT Osmotica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADRO Aduro Biotech	N/A	8.91	8.91
EVFM Evofem Biosciences	N/A	0.13	0.10
LXRX Lexicon Pharmaceuticals	1.07	5.60	5.58
OSMT Osmotica Pharmaceuticals	N/A	0.43	0.42
SNDX Syndax Pharmaceuticals	N/A	10.00	10.00

Ownership

Institutional Ownership

Company	Institutional Ownership
ADRO Aduro Biotech	49.93%
EVFM Evofem Biosciences	0.22%
LXRX Lexicon Pharmaceuticals	74.70%
OSMT Osmotica Pharmaceuticals	46.18%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ADRO Aduro Biotech	5.90%
EVFM Evofem Biosciences	0.21%
LXRX Lexicon Pharmaceuticals	6.80%
OSMT Osmotica Pharmaceuticals	5.22%
SNDX Syndax Pharmaceuticals	4.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADRO Aduro Biotech	152	16.21 million	N/A	Optionable
EVFM Evofem Biosciences	35	53.96 million	53.85 million	Not Optionable
LXRX Lexicon Pharmaceuticals	285	246.24 million	229.49 million	Optionable
OSMT Osmotica Pharmaceuticals	302	62.59 million	59.32 million	Not Optionable
SNDX Syndax Pharmaceuticals	184	84.96 million	81.48 million	Optionable

LXRX, SNDX, EVFM, ADRO, and OSMT Headlines

Source	Headline
	Financial Analysis: Syndax Pharmaceuticals (NASDAQ:SNDX) and Biofrontera (NASDAQ:BFRI) americanbankingnews.com - April 18 at 4:10 AM
	Syndax Pharmaceuticals gets grant for inhibitors of menin-mll interaction for cancer treatment pharmaceutical-technology.com - April 15 at 1:51 PM
	Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum finance.yahoo.com - April 10 at 7:46 PM
	Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum prnewswire.com - April 10 at 4:05 PM
	Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN) markets.businessinsider.com - April 8 at 11:51 PM
	Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospects markets.businessinsider.com - April 8 at 6:50 PM
$Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session$	Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session prnewswire.com - April 8 at 7:00 AM
	Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) finanznachrichten.de - April 6 at 8:34 AM
	Crinetics Pharmaceuticals gains amid pitch at Sohn charity conference (update) msn.com - April 3 at 1:44 PM
	Syndax completes enrollment in AUGMENT-101 pivotal trial cohort of patients with r/r mNPM1 acute myeloid leukaemia pharmabiz.com - March 31 at 4:16 AM
	20 European Cities with Highest Weed Consumption msn.com - March 29 at 7:06 AM
	This longevity company is letting you check the ‘credit score’ for your health. Here are my surprising results and biological age msn.com - March 29 at 2:06 AM
	Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA msn.com - March 28 at 11:04 AM
$Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia$	Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia finance.yahoo.com - March 28 at 11:04 AM
	Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA zacks.com - March 28 at 10:56 AM
	Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope seekingalpha.com - March 28 at 7:54 AM
	Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Quanterix (QTRX) markets.businessinsider.com - March 27 at 1:32 PM
	Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 4.9% marketbeat.com - March 27 at 12:44 PM
	Traders Purchase Large Volume of Syndax Pharmaceuticals Put Options (NASDAQ:SNDX) marketbeat.com - March 27 at 11:45 AM
	Syndax Says Revumenib NDA Granted FDA Priority Review marketwatch.com - March 27 at 8:32 AM
	Syndax Announces FDA Priority Review Of NDA For Revumenib For Treatment Of R/R KMT2Ar Acute Leukemia markets.businessinsider.com - March 27 at 8:32 AM
	FDA grants priority review for Syndax leukemia drug, sets action date msn.com - March 27 at 8:32 AM
$Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia$	Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia finance.yahoo.com - March 27 at 8:32 AM
	Syndax Pharmaceuticals' (SNDX) Buy Rating Reiterated at HC Wainwright marketbeat.com - March 27 at 8:18 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aduro Biotech

NASDAQ:ADRO

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Evofem Biosciences

NASDAQ:EVFM

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Lexicon Pharmaceuticals

NASDAQ:LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Osmotica Pharmaceuticals

NASDAQ:OSMT

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.

Syndax Pharmaceuticals

NASDAQ:SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial